Suppr超能文献

C5a/C5aR-白细胞介素-17A轴在慢性移植物抗宿主病中的新作用

Emerging role of C5a/C5aR IL-17A axis in cGVHD.

作者信息

Chen Xiaomei, Lai Peilong, Wang Yulian, He Chang, Wu Suijing, Huang Xin, Geng Suxia, Luo Chengwei, Ling Wei, Zeng Lingji, Li Peng, Jiang Zhiwu, Weng Jianyu, Du Xin

机构信息

The Second School of Clinical Medical, Southern Medical University Guangzhou 510515, P. R. China.

Department of Hematology, Guangdong General Hospital, Guangdong Academy of Medical Sciences Guangzhou 510080, Guangdong, P. R. China.

出版信息

Am J Transl Res. 2018 Jul 15;10(7):2148-2157. eCollection 2018.

Abstract

Chronic graft-versus-host disease (cGVHD) manifests with features characteristic of autoimmune disease with organs attacked by pathogenic Th17 cells. However, the mechanism of Th17 cells generation in the setting of cGVHD is still unclear. Here we defined C5a/C5aR-IL-17Aaxis as a novel signaling that required in the pathologies of cGVHD. We firstly found a positive link between complement activation and the Th17 cells in patients with cGVHD. C5a, a critical component of complements, promoted the generation of Th17 cells and inhibition of the receptor for C5a (C5aR) reduced the Th17-bias response. Of note, C5aR blockade by PMX53 could suppress the generation of IL-17A-expressing Th17 cells and retard the onset and progression of cGVHD . Overall, our results provide new mechanistic insights that activation of C5a-C5aR signaling was required for IL-17A-induced immune responses in cGVHD and define novel molecular targets for developing effective therapeutics for cGVHD.

摘要

慢性移植物抗宿主病(cGVHD)表现出自身免疫性疾病的特征,其器官受到致病性Th17细胞的攻击。然而,cGVHD背景下Th17细胞产生的机制仍不清楚。在此,我们将C5a/C5aR-IL-17A轴定义为cGVHD病理过程中所需的一种新信号通路。我们首先发现cGVHD患者补体激活与Th17细胞之间存在正相关。补体的关键成分C5a可促进Th17细胞的产生,而抑制C5a受体(C5aR)可减少Th17偏向性反应。值得注意的是,PMX53阻断C5aR可抑制表达IL-17A的Th17细胞的产生,并延缓cGVHD的发生和进展。总体而言,我们的结果提供了新的机制见解,即C5a-C5aR信号通路的激活是cGVHD中IL-17A诱导的免疫反应所必需的,并确定了开发cGVHD有效治疗方法的新分子靶点。

相似文献

1
Emerging role of C5a/C5aR IL-17A axis in cGVHD.
Am J Transl Res. 2018 Jul 15;10(7):2148-2157. eCollection 2018.
2
Attenuation of cGVHD by C5a/C5aR blockade is associated with increased frequency of Treg.
Sci Rep. 2017 Jun 15;7(1):3603. doi: 10.1038/s41598-017-03700-1.
3
Complement component C5a permits the coexistence of pathogenic Th17 cells and type I IFN in lupus.
J Immunol. 2014 Oct 1;193(7):3288-95. doi: 10.4049/jimmunol.1401322. Epub 2014 Aug 22.
5
Regulatory effects of C5a on IL-17A, IL-17F, and IL-23.
Front Immunol. 2013 Jan 9;3:387. doi: 10.3389/fimmu.2012.00387. eCollection 2012.
7
A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD.
J Hematol Oncol. 2018 Dec 7;11(1):135. doi: 10.1186/s13045-018-0680-7.
9
C5a/C5aR pathway is essential for up-regulating SphK1 expression through p38-MAPK activation in acute liver failure.
World J Gastroenterol. 2016 Dec 14;22(46):10148-10157. doi: 10.3748/wjg.v22.i46.10148.
10
C5aR activation in the absence of C5a: A new disease mechanism of autoimmune hemolytic anemia in mice.
Eur J Immunol. 2018 Apr;48(4):696-704. doi: 10.1002/eji.201747238. Epub 2018 Jan 15.

引用本文的文献

1
Diagnostic and therapeutic role of non-coding RNAs regulating programmed cell death in melanoma.
Front Oncol. 2024 Dec 24;14:1476684. doi: 10.3389/fonc.2024.1476684. eCollection 2024.
2
Hemostasis and complement in allogeneic hematopoietic stem cell transplantation: clinical significance of two interactive systems.
Bone Marrow Transplant. 2024 Oct;59(10):1349-1359. doi: 10.1038/s41409-024-02362-8. Epub 2024 Jul 14.
4
A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement.
Bone Marrow Transplant. 2023 Sep;58(9):991-999. doi: 10.1038/s41409-023-01996-4. Epub 2023 May 18.
5
The Gut Bacteria Dysbiosis Contributes to Chronic Graft-Versus-Host Disease Associated With a Treg/Th1 Ratio Imbalance.
Front Microbiol. 2022 Sep 8;13:813576. doi: 10.3389/fmicb.2022.813576. eCollection 2022.
6
Interleukin-17 pathways in systemic sclerosis-associated fibrosis.
Rheumatol Int. 2019 Jul;39(7):1135-1143. doi: 10.1007/s00296-019-04317-5. Epub 2019 May 9.
7
Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics.
Front Immunol. 2019 Feb 27;10:337. doi: 10.3389/fimmu.2019.00337. eCollection 2019.

本文引用的文献

1
Reprint of: Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant. 2018 Mar;24(3S):S7-S14. doi: 10.1016/j.bbmt.2017.12.788.
2
Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment.
Semin Cell Dev Biol. 2019 Jan;85:153-163. doi: 10.1016/j.semcdb.2017.11.023. Epub 2017 Nov 23.
3
Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade.
Oncoimmunology. 2017 Jul 13;6(10):e1349587. doi: 10.1080/2162402X.2017.1349587. eCollection 2017.
4
Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
Nature. 2017 Mar 2;543(7643):108-112. doi: 10.1038/nature21368. Epub 2017 Feb 22.
5
Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.
Blood. 2017 Jan 5;129(1):13-21. doi: 10.1182/blood-2016-06-686618. Epub 2016 Nov 7.
6
Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.
J Hematol Oncol. 2016 Jul 4;9(1):53. doi: 10.1186/s13045-016-0281-2.
7
RBPJ Controls Development of Pathogenic Th17 Cells by Regulating IL-23 Receptor Expression.
Cell Rep. 2016 Jul 12;16(2):392-404. doi: 10.1016/j.celrep.2016.05.088. Epub 2016 Jun 23.
8
The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation.
J Hematol Oncol. 2016 May 18;9(1):46. doi: 10.1186/s13045-016-0276-z.
10
Complement component C5a permits the coexistence of pathogenic Th17 cells and type I IFN in lupus.
J Immunol. 2014 Oct 1;193(7):3288-95. doi: 10.4049/jimmunol.1401322. Epub 2014 Aug 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验